Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497677 | 0.84 | ALDH1A1 (0.44) | ALDH1A1ALPLALPIKDM4EHPGD | |
| SCHEMBL20582868 | 0.84 | ALDH1A1 (0.44) | ALDH1A1ALPLALPIKDM4EHPGD | |
| SCHEMBL2296280 | 0.81 | ALDH1A1 (0.41) | ALDH1A1ALPLALPIKDM4EHPGD | |
| SCHEMBL7248921 | 0.78 | TDP1 (0.55) | ALDH1A1ALPLALPIGAACA2 | |
| SCHEMBL3487315 | 0.77 | LMNA (0.50) | ALDH1A1GAA | |
| SCHEMBL474102 | 0.77 | HTR2A (0.46) | ALDH1A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL24987673 | 0.76 | KDM4E (0.43) | ALDH1A1ALPLALPIKDM4EPPARA | |
| SCHEMBL6905828 | 0.75 | ALDH1A1 (0.49) | ALDH1A1ALPLALPIKDM4EHPGD | |
| SCHEMBL2761579 | 0.75 | KDM4E (0.39) | ALDH1A1ALPLALPIKDM4EPPARA | |
| SCHEMBL137921 | 0.75 | PPARA (0.43) | ALDH1A1ALPLALPIKDM4EPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | STUMP CRAIG A (US) | 2004-06-10 | — | — | US | disclosed |
| US-6534506-B2 | For therapy of cancer, neurofibromin benign proliferative disorder; blindness related to retinal vascularization; infections from hepatitis delta and related viruses; prophylaxis of restenosis; polycystic kidney disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-09-05 | — | — | US | disclosed |
| WO-2001077116-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001076693-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123497-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | ALDH1A1 3836/4885ALPL 3387/4885ALPI 3013/4885 |
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, PTAR1 | ALDH1A1 3634/4885ALPL 3427/4885ALPI 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.